Anti-interleukin 2 receptor monoclonal antibodies spare phenotypically distinct T suppressor cells in vivo and exert synergistic biological effects by unknown
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Antigen- or mitogen-induced de novo expression of high-affinity IL-2-Rs is a req-
uisite step in the course of T cell activation (1). The effectiveness of selective im-
munosuppressive therapy in organ transplantation using anti-IL-2-R mAbs has been
shown both in experimental settings and by encouraging early results from clinical
trials (2, 3). In our studies, ART18, a mouse anti-rat IgG1 antibody, prolonged the
survival of cardiac grafts transplanted across MHC barriers in several inbred rat
strain combinations (4, 5). We now demonstrate that anti-IL-2-R mAbs selectively
spare in vivo phenotypically distinct T cells with suppressor functions (Ts), and that
combined treatment with mAbs against functionally different epitopes may exert
strikingly synergistic effects.
Volume 167 June 1988 1981-1986
Materials and Methods
BriefDefinitive Report
mAbs.
￿
The panel of antibodies included ART18, ART65, and OX-39. Their production
and initial characterization have been described (6-8). Prepared from mouse ascites, they
immunoprecipitate the p55 chain of the rat IL-2-R (9) and contain -10 mg/ml IgG1 (ART
18 and ART-65) and N2 mg/ml IgG1 (OX-39). In contrast to ART-18, neither of these mAbs
affects IL-2-driven T cell proliferation; OX-39 and ART-18 inhibit bindingofIL-2 to its receptor,
whereas ART65 does not (6-8). Mouse-clarified ascites (IgGl, ti5 mg/ml) produced by MOPC
21 tumor line (Bionetics Laboratory Products, Kensington, MD) was used as a control.
mAb Binding Assay.
￿
II-2-dependent rat G2 T cells (106) were incubated for 1 hat 4°C with
increasing concentrations of 12'j-labeled ART-18, ART-65, or OX-39 (10). The cells were then
washed, separated from the unbound labeled material, and counted in a gamma counter.
The number of binding sites and the affinity of each mAb were calculated by Scatchard plot
analysis.
Animals and Grafting Technique.
￿
Inbred male adult Lewis rats (LEW, RTl1) served as
recipients of cardiac allografts from (LEW x BN)F, (RTI") hybrid or Wistar Furth (WF,
RTl°) donors (Harlan Sprague Dawley, Inc., Indianapolis, IN). Hearts were transplanted
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to recipient abdominal great vessels using microvascular techniques. Graft function was as-
sessed daily by palpation through the host flank; rejection was taken as the time of complete
cessation of myocardial contractions.
mAb Treatment.
￿
ART18, ART65, and OX-39 mAbs were administered to experimental
animals intravenously at doses of 25-300 wg/kgper d for 10 d starting the day of transplanta-
tion. There were 5-9 animals in each experimental group.
Cell Preparations.
￿
Single spleen cell (SL) suspensions were prepared by mincing and ex-
pressing SL through 60-gauge stainless steel mesh into RPMI-1640 medium (Gibco, Grand
Island, NY) supplemented with 5 mM Hepes, 2 MM L-glutamine, and 10% heat-inactivated
FCS (Associated Biomedic System, Buffalo, NY) . Erythrocytes were lysed by brieftreatment
with 0 .83% Tris-buffered ammonium chloride (pH 7 .21) . Nonadherent T cell-enriched
(>95%) populations from nylon wool columns were fractionated into CD4' (T helper/in-
ducer, W3/25') and CD8' (T suppressor/cytotoxic, OX8' ). subsets, as described (11) . Only
nonadherent negatively selected T cells (>90% viable, enriched >95% for the desired sub-
population) were adoptively transferred into syngeneic normal rats that received a test graft
24 h later. There were 4-7 animals in each group.
Statistical Analysis.
￿
The statistical differences between experimental groups were ascer-
tained using Student's t test.
Results
Binding ParametersforAnti-IL-2-R mAbs.
￿
Scatchard analysis revealed distinct binding
of iodinated mAbs to G2 target cells. The highest affinity was for OX-39 (kd = 8.26
x 10 -1°), lower for ART65 (kd = 1.2 x 10 - '), and least for ART18 (kd = 1.91 x
10-9). In contrast, ART-18 had the maximal number of molecules bound per G2
cell (75,000), followed by OX-39 (61,185), and ART-65 (27,702).
Therapeutic Efficacy ofAnti-IL-2-R mAbs.
￿
ART-18 therapy (300 gg/kg per d for 10
d, i.v.) prolongs the survival of (LEW x BN)F1 cardiac grafts in LEW recipients
to -21 d (acute rejection in untreated hosts occurs within 8 d, p < 0.001) (4). Simi-
larly, a 10-d course of ART65 (300 jig/kg per d) extended graft survival (MST ±
SD = 15 .5 ± 4.4 d, p < 0.01, as compared with ART-18-modified hosts). In con-
trast, therapy with OX-39 or with the control IgGl antibody never influenced the
tempo of rejection (8 t 1 and 7 ± 1 d, respectively).
The Selective Effect ofAnti-IL-2-R mAbs on T Cell Subsets.
￿
Recent work from this
laboratoryhas demonstrated sparing of Ts by ART-18 treatment (4, 12). Donor-specific
test graft survival is prolonged in naive syngeneic rats to 15 .0 ± 1 and 15.5 ± 0 .9
d after adoptive transfer of 100 x 106 unseparated SL or 50 x 106 CD8' T cells
harvested from mAb-conditioned animals 10 d after transplantation, respectively
(p < 0.001); CD4+ cells (40-50 x 106) were ineffectual (8.5 ± 0.5 d) . In the present
studies, transfer of 100 x 106 SL from ART-65-treated LEW recipients bearing well-
functioning (LEW x BN)F1 transplants extended the survival of specific test cardiac
allografts to 13 .6 t 2 .9 d (p < 0 .001, as compared with untreated controls). How-
ever, when SL from ART-65-treated recipients were separated into highly purified
and non-overlapping component parts, the CD4+ subset (50 x 106 cells) conferred
profound suppression to normal LEW, with prolongation of (LEW x BN)F1 test
grafts to lengths (MST t SD = 45 ± 17 .5 d) unprecedented in our previous ex-
perience; transfer of the same number of CD8` cells was less effective (14.5 ± 0 .7
d, p < 0.001). The third-party (WF) test grafts were always rejected within 10 d in
the comparable groups of secondary recipients. All the above experiments subse-
quently were repeated 4-7 times; the results were uniformly the same. Thus, IL-2-DI STEFANO ET AL . BRIEF DEFINITIVE REPORT
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FIGURE 1 .
￿
(LEW x BN)FI cardiac allograft survival
in LEW recipients treated with ART18 and/orART65
anti-IL-2-R mAb(s) (25 pg/kg per d, i.v. ; there were 5-9
animals in each experimental group) . (O)ART-65 (treat-
ment for 10 consecutive post-transplant days);(0)ART
18 (treatment for 10 consecutive post-transplant days);
(p)ART18 (treatment for the first 5 post-transplant
days) + ART-65 (treatment for the second 5 post-
transplant days) ; (A)ART-18 + ART-65 (treatment for
10 consecutive post-transplant days; (") untreated
controls .
R-targeted therapy selectively spares phenotypically distinct populations of Ts :
CD8+ in ART-18-treated animals and primarily CD4+ in ART-65-treated hosts .
The Effect of Combined ART-18 PlusART65mAb Treatment . Rat recipients of cardiac
allografts were treated with a combination ofART18 and ART-65 to target distinct
epitopes of the IL-2-R molecule, as well as to influence the selective in vivo effects
ofmAbs upon host Ts . Concomitant administration ofART-18 and ART-65 for 10 d
after transplantation in relatively low doses (25 wg/kg per d), only marginally oper-
ative on their own (graft survival = 13 .0 t 1 and 9.5 f 2 .5 d, respectively), proved
highly effective, with 3 of 10 cardiac allografts surviving indefinitely, five undergoing
rejection at periods>50 d, and the remaining grafts surviving -3 wk (Fig. 1) . Treat-
ment with ART-18 for the first 5 d after transplantation followed by ART-65 therapy
for the subsequent 5 d was less striking (16.8 ± 1.6 d) . Thus, ART-18 and ART-65
in combination exert an important synergistic effect in vivo by simultaneously tar-
geting IL-2-R+ cells activated in response to the allogeneic graft . In contrast,
therapy combining OX-39 with ART-18 did not improve survival beyond that ob-
served after ART-18 antibody alone (data not shown) .
Discussion
The present studies were designed to compare and correlate the in vitro and in
vivo immunosuppressive properties ofART-18, ART-65, and OX-39 (Table I), non-
crossreactive IgGI antibodies that recognize distinct epitopes on the p55 ß chain
of the rat Il-2-R (9) . Several questions can be posed based on the results of the ex-
periments .
WhyAremAbs oftheSame IsotypeandCommon Specificityfor thep55 SubunitoftheIL-2-R
Molecule not Equally Effective In Vivo? These experiments stress the lack of correla-
tionbetweenthe in vitro bindingparameters of anti-IL-2-R mAbs and theirbiolog-
ical efficacy in vivo. ART-18, despite its lower apparent affinity for the receptor, ex-
hibits potent immunosuppressiveproperties in vivo. In contrast, OX-39 in the same
dose did not influence acute rejection of cardiac allografts despite demonstrating
the highest affinity for its epitope and covering large numbers of binding sites per
target cell in vitro. Although each mAb interacts specifically with a given epitope
in vivo, the three-dimensional structure of the epitope may occur on both related
and unrelated molecules (13) . For example, ART-62, a mouse anti-rat IgG1 anti-
body that blocksT cell function and inhibits II-2-dependentT cell proliferation in
vitro, lacksbiological activity in vivo, despite recognizingbroadly the epitope of the
ratMHC Class I antigen present on various cells including erythrocytes (12) . It is1984
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TABLE I
The In Vitro and In Vivo Properties of Mouse Anti-rat IL-2-R rnAbs
' The in vitro properties of mAbs were tested using the IL-2-dependent rat G2 T cell line. The apparent
affinities ofmAbs and the number ofbinding sites on target cells were calculated using Scatchard plot anal-
ysis. The effects of mAbs upon IL-2 binding and IL-2-dependent T cell proliferation were tested as described
(6-8).
$ The therapeutic efficacy of mAbs was evaluated in the rat cardiac allograft model ([LEW x BNJF1 - LEW;
acute rejection in untreated recipients occurs within 8 d). Antibodies were administered for 10 consecutive
days after transplantation (300 ug/kg per d i.v.). Mean graft survival times are shown (n = 5-9).
§ The "sparing" of putative Ts was tested in adoptive transfer studies . Negatively selected CD8' (0X8'
W3/25- ), or CD4' (W3/25' OX8- ) spleen T cells (40-50 x 106) from ART-18 or ART-65 mAb-treated
heart graft recipients were administered into naive syngeneic rats that were challenged with a donor-specific
test cardiac allograft 24 h later. Mean test graft survival times (n = 4-7): 14-16 d ( + ); 45 d ( + + + ) ;
8-10 d ( - ).
possible that OX-39 may be actively "captured" by unrelated cells and tissues ex-
pressing the common epitope in vivo, and therefore, it is unable to reach the related
targets. Indeed, recent studies demonstrate that this mAb, in contrast to ART18,
reacts with N3% of rat thymic dendritic cells and N2To of rat thymocytes (8).
Is Blocking of T CellActivity by Anti-IL-2-R mAbs Requiredfor TheirIn Vivo Efects?
￿
The
present results in an allograft model complement recently reported local graft-vs.-
host reaction trials that demonstrate the immunosuppressive efficacy ofART-65, an
antibody that in contrast to ART-18 affects neither IL-2 binding nor IL-2-dependent
T cell growth (7). Inhibition of T cell function may not be a prerequisite for suc-
cessful IL-2-R-targeted therapy as the in vivo mode of action of these mAbs is to
eliminate, rather than to inhibit expansion of, IL-2-R+ effector cells. Preliminary
data on the use of ART-18 isotype switch variants suggest antibody-dependent cell
cytotoxicity to be primarily responsible for the effect observed in our studies (14).
Alternatively, treatment with M7/20, a rat anti-mouse IL-2-R mAb of IgM isotype
and binding parameters identical to ART18, obviated delayed-type hypersensitivity
responses in normal but not in complement deficient mice (15), suggesting that mAbs
ideally should fix terminal complement components and inhibit T cell function.
Why Do Anti-IL-2-R mAbs Selectively Spare Phenotypically Distinct TCell Subsets?
￿
The
heavy glycosylation ofthe Q chain ofthe IL-2-R molecule may explain the discrepancy
between the molecular mass of the receptor calculated from the amino acid sequence
(30 kD) and the actual molecular mass of the isolated receptor (55 kD) (16).
Non-random glycosylation ofthe IL-2-R molecule on host lymphocytes may lead
to divergent accessibility ofT cell subsets by anti-IL-2-R mAbs with resultant sparing
of distinct Ts subpopulations. Thus, ART-18 treatment does not affect the majority
of CD8 + Ts but inactivates the CD4 + subset including CD4 + Ts, whereas ART-65
therapy preserves primarily CD4+ Ts. The practical relevance of this observation
is of major importance, as sparing of phenotypically distinct Ts may contribute to
In vitro activities"
Binding parameters Inhibition of: In vivo activities
Affinity Number of IL-2 IL-2 pro- Graft Ts sparing
mAb Isotype kD binding sites binding liferation survivalt CD8' CD4'
ART-18 IgGl 1 .91 x to-9 75,000 + + 21 d + -
ART-65 IgG1 1 .20 x 10-9 27,702 - - 16 d + + + +
OX-39 IgG1 8.26 x 10-to 61,185 + - 8 d ND NDDI STEFANO ET AL. BRIEF DEFINITIVE REPORT
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the unprecedented graft prolongation in rats treated with the combination of ART
18 and ART-65. It is also conceivable that ART-18 and ART-65 bind to the epitopes
on different a chains of CD4+ and CD8+ cells; alternative mRNA splicing may
occur (17) . It remains to be determined whether the long-lasting therapeutic effect
after ART-18 plus ART-65 treatment was achieved by preventing association of p55
R and p75 a chains, so that no high-affinity receptors can be formed.
Summary
The therapeutic efficacies of ART-18, ART-65, and OX-39, mouse antibodies of
IgG1 isotype recognizing distinct epitopes of the p55 R chain of the rat IL-2-R mol-
ecule, were probed in LEW rat recipients of (LEW x BN)F1 heterotopic cardiac
allografts (acute rejection in untreated hosts occurs within 8 d). A 10-d course with
ART-18 prolongs graft survival to -21 d (p < 0 .001). Therapy with ART-65, but not
with OX-39, was effective (graft survival ti 16 and 8 d, respectively). Anti-IL-2-R.
mAb treatment selectively spared T cells with donor-specific suppressor functions;
the CD8+ (OX8+ W3/25 - ) fraction from ART-18-modified recipients, and pri-
marily the CD4 + (W3/25 + OX8- ) subset from ART-65-treated hosts conferred un-
responsiveness to naive syngeneic rats after adoptive transfer, increasing test graft
survival to -16 and 45 d, respectively. Concomitant administration of ART-18 and
ART-65 to recipient animals in relatively low doses exerted a strikingly synergistic
effect, with 30% of the transplants surviving indefinitely and 50% undergoing late
rejection over 50 d. These studies provide evidence that anti-IL-2-R mAbs selec-
tively spare phenotypically distinct T cells with suppressor functions. The data also
suggest that in vivo targeting of functionally different IL-2-R epitopes may produce
synergistic biological effects .
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